Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alitretinoin in Severe Refractory Chronic Hand Dermatitis (BACH)
NCT00124475Phase 3Completed
- Sponsor
- Basilea Pharmaceutica
- Start
- Dec 2004
- Primary completion
- Oct 2006
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of alitretinoin in chronic hand dermatitis (CHE) (3 arms), sponsored by Basilea Pharmaceutica. Primary endpoint: Physician's Global Assessment at 24 weeks. Started Dec 2004; status: completed.
02
Drugs
alitretinoin
03
Conditions
chronic hand dermatitis (CHE)
Beyond the preview
Go deeper on NCT00124475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00124475.